Shots:

• The companies present the findings from a new exploratory sub-analysis of the P-III EMPEROR-Reduced study demonstrating that Jardiance (empagliflozin) reduced the risk of adverse CV by 25% and kidney events by 50% in adults with HFrEF with/out diabetes regardless of CKD status at ASN Week 2020
• In all patient cohorts participating in the EMPEROR-Reduced trial- the safety profile was like the well-established safety profile of Jardiance. In Mar’2020- the US FDA granted FT designation to the therapy for CKD based on its ongoing EMPA-KIDNEY study with its expected results in 2022
• In 2019- the US FDA granted FT designation to Jardiance for the reduction of the risk of CV death and hospitalization for heart failure in people with HF based on its EMPEROR program- which consists of two P-III studies EMPEROR-Reduced & EMPEROR-Preserved

 ­ Ref: PRNewswire | Image: Eli Lilly